bacteriophages targeting Pseudomonas aeruginosa

Bacteriophages targeting *Pseudomonas aeruginosa* represent a therapeutic strategy that uses viruses (bacteriophages) to specifically infect and kill *P. aeruginosa* bacteria. [9] This approach is particularly promising for treating infections caused by multidrug-resistant (MDR) strains of *P. aeruginosa*, a pathogen responsible for severe and chronic infections in conditions such as cystic fibrosis (CF), bronchiectasis, burn wounds, and chronic ear infections. [1, 5, 8] The mechanism of action involves the phages binding to specific receptors on the bacterial cell surface, injecting their genetic material, and utilizing the host cell's machinery for replication, which culminates in bacterial cell lysis and death. [9] To enhance efficacy and mitigate the development of bacterial resistance, these therapies are commonly formulated as "cocktails" containing several distinct phage strains. [1, 8] Multiple biotechnology companies are actively developing these phage therapies, with several candidates advancing through clinical trials for various indications. [2, 7, 12] The treatments are being investigated for several routes of administration, including inhalation for respiratory infections, as well as intravenous and topical applications. [3, 9, 14]

Brand names

Biophage-PA

Other names

phage therapy for Pseudomonas aeruginosaP. aeruginosa bacteriophage therapyanti-Pseudomonas phage therapy